Market Intelligence, Clinical Progress, and High-Purity Reagents for Central Nervous System & Obstetric Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OXTR (Oxytocin Receptor) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Target | OXTR Lentivirus Premade Particles / Full-Length Membrane Prep For stable cell line generation or binding assays. Sequence Verified, Native Conformation, >95% purity, <1EU/ug endotoxin. |
View OXTR Products |
| Gene Delivery | OXTR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer (>10^8 TU/ml), qPCR verified. |
View OXTR Products |
| Benchmark Ab | Anti-OXTR Control Antibody Recombinant positive control for assay validation. Sequence Verified. |
View OXTR Products |
| Validator | OXTR siRNA Set For knockdown verification and specificity checks. Three unique targets. |
View OXTR Products |
| Related Target A | AVPR1A (Vasopressin V1a) High homology counter-target for selectivity screening. |
View AVPR1A Products |
| Related Target B | AVPR1B (Vasopressin V1b) Off-target liability for neuropsychiatric applications. |
View AVPR1B Products |
| Related Target C | AVPR2 (Vasopressin V2) Essential for off-target renal effect profiling. |
View AVPR2 Products |
| Related Target D | CD38 (NADase) Oxytocin secretion regulation pathway partner for combination studies. |
View CD38 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex GPCR Conformation & Signaling Integrity | Lentivirus-mediated stable cell pools preserve 7TM structure and native glycosylation for calcium flux and cAMP assays. |
| Vasopressin Receptor Subfamily Selectivity (AVPR1A/AVPR1B/AVPR2) | Homology panel with sequence-verified orthologs (human/cyno/mouse) for counter-screening; mass spec confirmed purity >95%. |
| Cross-species Translation (Human/Mouse/Cyno) | Ortholog-specific Lentivirus and membrane preps available with sequence-verified identity. |
| GPCR Internalization Trafficking | High-titer Lentivirus for stable GFP-tag integration in HEK293; native glycosylation preserved. |
| Lack of Reliable Controls | Sequence-verified recombinant benchmark antibodies and endotoxin-controlled tools (<1EU/ug). |
| Assay False Positives | Validated siRNA sets (knockdown >75%) included for specificity checks. |
Live OXTR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OXTR therapeutics is intensifying, with major players shifting focus from traditional peptide analogs to highly selective small molecules, biased GPCR modulators, and allosteric compounds. First-generation therapies for labor induction and preterm labor (e.g., Atosiban, Carbetocin) have reached clinical maturity, while the next wave of R&D is heavily targeting CNS indications including autism spectrum disorder (ASD), schizophrenia, postpartum depression, and social anxiety. Overcoming blood-brain barrier penetration and the structural similarity with vasopressin receptors remain the most significant barriers. Key trends include brain-penetrant small molecule agonists for ASD, peripherally restricted antagonists for preterm labor without CNS effects, and biased signaling (Gq vs Gi) agonists to reduce receptor desensitization. The recent failure of intranasal oxytocin Phase III trials highlights the urgent need for stable, cell-based selectivity assays and allosteric modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Sage Therapeutics, Roche, OptiNose | Autism, Social Anxiety, Schizophrenia | Calcium Flux & cAMP Biased Signaling (need stable OXTR+ cell lines via Lentivirus) |
| Small Molecule Antagonist | GSK, Merck, ObsEva, Ferring | Preterm Labor | Selectivity vs AVPR1A/AVPR2 (need homology panel with verified sequences) |
| Peptide Analog | Academic Consortia, Linical, J&J | Schizophrenia, PTSD, Postpartum Depression | Receptor Internalization & Desensitization Assay (need high-expression Lentivirus systems) |
| Allosteric Modulator | Biotech Startups (Undisclosed) | Prader-Willi Syndrome | Binding Site Competition (need full-length membrane protein with native conformation) |
| Monoclonal Antibody | Academic / Early Biotech | Research / Diagnostics | Binding Validation (need sequence-verified control antibodies) |
Key Genetic Variants of OXTR
Important natural variants include:
- rs237906 (dbSNP) – associated with altered receptor expression.
- rs4686302 (dbSNP) – linked to changes in signaling efficiency.
- Mutation preventing phosphorylation by PRKD1 (UniProt VAR_091521) – leads to decreased G(q)-dependent signaling, highlighting the importance of cellular context for biased agonism screening.
These variants underscore the need for sequence-verified reagents and cell lines that accurately reflect the target genotype.